Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALT NASDAQ:KROS NASDAQ:MNMD NASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$2.45+8.9%$1.69$0.73▼$3.90$155.06M0.7413,487 shs459,022 shsKROSKeros Therapeutics$14.47+1.0%$13.97$9.12▼$72.37$587.70M1.26864,959 shs592,601 shsMNMDMind Medicine (MindMed)$8.10+4.9%$7.04$4.70▼$10.44$611.96M2.451.33 million shs1.33 million shsTLRYTilray Brands$0.64-5.6%$0.44$0.35▼$2.15$641.24M1.8230.90 million shs51.03 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics+7.66%+3.69%+70.45%+74.42%-5.06%KROSKeros Therapeutics+2.95%+6.79%+1.63%+16.99%-66.50%MNMDMind Medicine (MindMed)+3.35%+9.04%-0.52%+50.19%+8.73%TLRYTilray Brands+14.37%+39.14%+64.66%+33.58%-61.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGALTGalectin Therapeutics1.4075 of 5 stars3.50.00.00.01.91.70.0KROSKeros Therapeutics2.5821 of 5 stars3.33.00.00.02.03.30.0MNMDMind Medicine (MindMed)2.9838 of 5 stars3.63.00.00.03.40.80.6TLRYTilray Brands2.173 of 5 stars3.11.00.00.03.80.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 3.00Buy$6.00144.90% UpsideKROSKeros Therapeutics 2.50Moderate Buy$30.56111.16% UpsideMNMDMind Medicine (MindMed) 3.27Buy$25.50214.81% UpsideTLRYTilray Brands 2.25Hold$1.92200.84% UpsideCurrent Analyst Ratings BreakdownLatest GALT, KROS, TLRY, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.005/30/2025KROSKeros TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$15.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025KROSKeros TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$41.00 ➝ $26.005/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $25.004/14/2025TLRYTilray BrandsRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.68) per shareN/AKROSKeros Therapeutics$214.71M2.74N/AN/A$14.11 per share1.03MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ATLRYTilray Brands$788.94M0.81N/AN/A$4.14 per share0.15Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)KROSKeros Therapeutics-$187.35M-$0.18N/AN/AN/A1.96%0.75%0.69%8/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)TLRYTilray Brands-$244.98M-$1.05N/AN/AN/A-113.85%-7.40%-6.02%8/4/2025 (Estimated)Latest GALT, KROS, TLRY, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025KROSKeros Therapeutics-$1.13N/AN/AN/A$3.83 millionN/A8/4/2025Q4 2025TLRYTilray Brands-$0.03N/AN/AN/AN/AN/A5/15/2025Q1 2025GALTGalectin Therapeutics-$0.20-$0.15+$0.05-$0.15N/AN/A5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/6/2025Q1 2025KROSKeros Therapeutics-$0.01$3.62+$3.63$3.62$84.62 million$211.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATLRYTilray BrandsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A0.080.08KROSKeros TherapeuticsN/A19.2919.29MNMDMind Medicine (MindMed)0.107.277.27TLRYTilray Brands0.122.621.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%KROSKeros Therapeutics71.56%MNMDMind Medicine (MindMed)27.91%TLRYTilray Brands9.35%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics50.10%KROSKeros Therapeutics20.60%MNMDMind Medicine (MindMed)2.45%TLRYTilray Brands0.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics963.29 million31.58 millionOptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionableMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableTLRYTilray Brands2,6501.01 billion1.00 billionOptionableGALT, KROS, TLRY, and MNMD HeadlinesRecent News About These CompaniesTilray Brands (NASDAQ:TLRY) Trading Down 3.1% - Should You Sell?July 10 at 1:13 PM | marketbeat.comPromising Cannabis Stocks To Watch Now - July 10thJuly 10 at 12:45 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Up 14.5% - Here's WhyJuly 9 at 5:39 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Sees Large Volume Increase - Should You Buy?July 9 at 2:12 PM | marketbeat.comBest Cannabis Stocks To Research - July 9thJuly 9 at 1:33 PM | marketbeat.comTilray Brands, Inc. to Release Q4 and Full Fiscal Year 2025 Financial Results on July 28, 2025July 9 at 7:29 AM | quiverquant.comQTilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025July 9 at 7:00 AM | globenewswire.comTilray Brands (NASDAQ:TLRY) Shares Up 13.6% - What's Next?July 8 at 2:41 PM | marketbeat.comBest Cannabis Stocks To Keep An Eye On - July 8thJuly 8 at 12:54 PM | marketbeat.comTilray Brands: Gambling A Little Money Now Could Generate Sizable Future PayoffJuly 8 at 12:00 PM | seekingalpha.comHere's Why Tilray Brands, Inc. (TLRY) Fell More Than Broader MarketJuly 7 at 7:16 PM | zacks.comCannabis Stocks To Follow Now - July 7thJuly 7 at 12:12 PM | marketbeat.comTilray Brands (NASDAQ:TLRY) Stock Price Down 10% - Here's What HappenedJuly 7 at 11:55 AM | marketbeat.comTilray Brands (NASDAQ:TLRY) Downgraded to Strong Sell Rating by Wall Street ZenJuly 6, 2025 | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Stock Rating Lowered by Wall Street ZenJuly 5, 2025 | marketbeat.comTilray Brands Sees Unusually Large Options Volume (NASDAQ:TLRY)July 5, 2025 | americanbankingnews.comTilray Brands (NASDAQ:TLRY) Stock Price Up 9.4% - Still a Buy?July 4, 2025 | marketbeat.comHere’s why the Tilray Brands stock price has implodedJuly 3, 2025 | invezz.comIStock Traders Buy Large Volume of Tilray Brands Call Options (NASDAQ:TLRY)July 3, 2025 | marketbeat.comCannabis Stocks To Keep An Eye On - July 3rdJuly 3, 2025 | marketbeat.comTilray Brands (NASDAQ:TLRY) Trading 4.1% Higher - Here's WhyJuly 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGALT, KROS, TLRY, and MNMD Company DescriptionsGalectin Therapeutics NASDAQ:GALT$2.45 +0.20 (+8.89%) Closing price 04:00 PM EasternExtended Trading$2.28 -0.18 (-7.14%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.Keros Therapeutics NASDAQ:KROS$14.47 +0.15 (+1.05%) Closing price 04:00 PM EasternExtended Trading$14.46 -0.01 (-0.07%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Mind Medicine (MindMed) NASDAQ:MNMD$8.10 +0.38 (+4.92%) Closing price 04:00 PM EasternExtended Trading$7.97 -0.13 (-1.62%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Tilray Brands NASDAQ:TLRY$0.64 -0.04 (-5.63%) Closing price 04:00 PM EasternExtended Trading$0.64 +0.00 (+0.46%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain BigBear.ai: Why a 90% Rally Could Be Just the Start Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation SoundHound Rises as Short Sellers Exit and AI Demand Grows Alphabet: Technical Momentum Is Starting to Turn Boeing's Rebound Is Well Underway—But Is It Too Late? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
